Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 expression is upregulated in TC cells. Western blotting was used to detect the expression of PRMT1 in human TC cell lines 8505C and CAL62, and in the human normal thyroid cell line Nthy-ori 3-1. **P<0.01 vs. Nthy-ori 3-1. PRMT1, protein arginine methyltransferase 1; TC, thyroid carcinoma.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 µM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Expressing, Western Blot

Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 downregulation inhibits cell proliferation and migration and promotes cell apoptosis in TC. (A and B) RT-qPCR and western bolting were used to determine the expression of PRMT1 in 8505C cells following various treatments. (C and D) CCK-8 and colony formation assays were used to assess cell viability and proliferation, respectively, of treated 8050C cells. (E) Flow cytometry was used to determine apoptosis of treated 8505C cells. (F and G) Wound healing (magnification, ×100) and Transwell (magnification, ×200) assays were used to assess cell migration of the treated 8505C cells. *P<0.05, **P<0.01 vs. si-NC; # P<0.05, ## P<0.01 vs. si-PRMT1; ^^ P<0.01 vs. 10 µM AMI-1. PRMT1, protein arginine methyltransferase 1; TC, thyroid carcinoma; si-NC, small interfering RNA negative control.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 µM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Migration, Quantitative RT-PCR, Western Blot, Expressing, CCK-8 Assay, Flow Cytometry, Small Interfering RNA, Negative Control

Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 knockdown suppresses cell metastasis and downregulates expression of ZEB1 and H4R3me2as in TC. (A) IF analyzed the contents of E-cadherin and vimentin in 8505C cells, magnification=400×. (B) Western blotting was used to assess the protein expression levels of E-cadherin, vimentin, H4R3me2as, and ZEB1 in 8505C cells. The 8505C cells were transfected with si-NC or si-PRMT1. *P<0.05, **P<0.01 compared with si-NC; ## P<0.01 compared with si-PRMT1; ^^ P<0.01 compared with 10 µM AMI-1. Each experiment was conducted at least thrice. PRMT1, protein arginine methyltransferase 1; ZEB1, zinc finger e-box binding homeobox1, H4R3me2as, asymmetric demethylation of H4 at the third arginine residue; TC, thyroid carcinoma; si-NC, small interfering RNA negative control.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 µM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Knockdown, Expressing, Western Blot, Transfection, Binding Assay, Residue, Small Interfering RNA, Negative Control

Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 overexpression accelerates TC progression and upregulates the expression of ZEB1 and H4R3me2as. (A and B) RT-qPCR and western bolting were used to assess the expression of PRMT1 in BCPAP cells. (C and D) The CCK-8 and colony formation analyses were used to determine BCPAP cell viability and proliferation, respectively. (E) Flow cytometry was used to analyze BCPAP cell apoptosis. (F and G) Wound healing (magnification, ×100) and Transwell (magnification, ×200) assays were used to assess cell migration of BCPAP cells. (H) IF was used to assess E-cadherin and vimentin expression in BCPAP cells. Magnification, ×400. (I) Western blotting was used to assess the protein expression of E-cadherin, vimentin, H4R3me2as, and ZEB1 in BCPAP cells. BCPAP cells were transfected with oe-PRMT1. *P<0.05, **P<0.01 vs. with VE. PRMT1, protein arginine methyltransferase 1; ZEB1, zinc finger e-box binding homeobox1; H4R3me2as, asymmetric demethylation of H4 at the third arginine residue; TC, thyroid carcinoma; oe-PRMT1, overexpression-PRMT1; VE, vector.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 µM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Over Expression, Expressing, Quantitative RT-PCR, Western Blot, CCK-8 Assay, Flow Cytometry, Migration, Transfection, Binding Assay, Residue, Plasmid Preparation

Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 overexpression accelerates TC progression through the activation of ZEB1/H4R3me2as. (A) RT-qPCR was used to assess the expression of ZEB1 in BCPAP cells transfected with si-ZEB1. (B) mRNA expression of PRMT1 and ZEB1 in multiple group of cells. (C and D) CCK-8 and colony formation assays were used to test BCPAP cell viability and proliferation, respectively. (E and F) Wound healing and Transwell assays were used to assess cell migration of BCPAP cells. Scale bar, 50 µM. (G) Western blotting was used to measure the protein expression levels of E-cadherin, vimentin, and H4R3me2as in BCPAP cells. BCPAP cells were transfected with oe-PRMT1 and/or si-ZEB1. **P<0.01 vs. VE group, ## P<0.01 vs. oe-PRMT1 + si-NC group. PRMT1, protein arginine methyltransferase 1; ZEB1, zinc finger e-box binding homeobox1; H4R3me2as, asymmetric demethylation of H4 at the third arginine residue; TC, thyroid carcinoma; oe-PRMT1, overexpression-PRMT1; VE, vector.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 µM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Over Expression, Activation Assay, Quantitative RT-PCR, Expressing, Transfection, CCK-8 Assay, Migration, Western Blot, Binding Assay, Residue, Plasmid Preparation

Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 knockdown reduces tumor growth and metastasis by inhibiting ZEB1/H4R3me2as in a xenograft model. (A) PRMT1 protein expression in TC tissues (B) Excised tumors from the mouse model of TC. (C) H&E staining of TC tissues. Magnification, ×200. (D) Image of pulmonary nodules and number of pulmonary nodules. (E) TUNEL assays were used to assess apoptosis in xenograft model mice. Magnification, ×400. (F) Western blotting was to measure the protein expression levels of E-cadherin, vimentin, H4R3me2as, and ZEB1 in TC tissues. BALB/C nude mice were subcutaneously injected with treated 8505C cells. *P<0.05, **P<0.01 vs. si-NC; # P<0.05, ## P<0.01 vs. si-PRMT1; ^ P<0.05; ^^ P<0.01 vs. 10 µM AMI-1. PRMT1, protein arginine methyltransferase 1; ZEB1, zinc finger e-box binding homeobox1; H4R3me2as, asymmetric demethylation of H4 at the third arginine residue; TC, thyroid carcinoma; si-NC, small interfering RNA negative control.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 µM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Knockdown, Expressing, Staining, TUNEL Assay, Western Blot, Injection, Binding Assay, Residue, Small Interfering RNA, Negative Control